Jazz Pharmaceuticals plc
JAZZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.89B
Close$
$570.41
166.5% upside
Current Fair Value
166.5% upsideUndervalued by 166.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.89 Billion |
|---|---|
| Enterprise Value | $16.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.84 |
| Beta | 0.32 |
| Outstanding Shares | 63,200,000 |
Return
| Return on Equity | 19.59% |
|---|---|
| Return on Assets | 8.49% |
| Return on Invested Capital | 8.74% |
Valuation & Multiples
| P/E Ratio | 14.08 |
|---|---|
| PEG | -11.1 |
| Price to Sales | 2.97 |
| Price to Book Ratio | 2.85 |
| Enterprise Value to Revenue | 3.64 |
| Enterprise Value to EBIT | 21.65 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 0.93 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$6.18
Average shareholder expectationRevenue Estimate
$1.11 B
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$6.26
Average shareholder expectationRevenue Estimate
$1.21 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 106.98% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.09%▼ 101.64% |
|---|---|
| Total Invested | $450.82M▼ 97.11% |
| Investors Holding | 134▼ 528.00% |
ESG Score
No data
About Jazz Pharmaceuticals plc
1,210 employeesJazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...